Friulchem SpA
MIL:FCM

Watchlist Manager
Friulchem SpA Logo
Friulchem SpA
MIL:FCM
Watchlist
Price: 0.88 EUR
Market Cap: 5.3m EUR
Have any thoughts about
Friulchem SpA?
Write Note

Friulchem SpA
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Friulchem SpA
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Friulchem SpA
MIL:FCM
Total Current Liabilities
€17.5m
CAGR 3-Years
46%
CAGR 5-Years
37%
CAGR 10-Years
N/A
Newron Pharmaceuticals SpA
SIX:NWRN
Total Current Liabilities
€5.4m
CAGR 3-Years
15%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
Total Current Liabilities
€887.2m
CAGR 3-Years
13%
CAGR 5-Years
16%
CAGR 10-Years
10%
P
Pierrel SpA
MIL:PRL
Total Current Liabilities
€19.9m
CAGR 3-Years
29%
CAGR 5-Years
15%
CAGR 10-Years
-10%
Shedir Pharma Srl Unipersonale
MIL:SHE
Total Current Liabilities
€14.4m
CAGR 3-Years
5%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
No Stocks Found

Friulchem SpA
Glance View

Market Cap
5.3m EUR
Industry
Pharmaceuticals

Friulchem SpA engages in the research and development of pharmaceutical products for third party contract development and manufacturing organizations. The company is headquartered in Vivaro, Pordenone and currently employs 37 full-time employees. The company went IPO on 2019-07-25.

FCM Intrinsic Value
4.31 EUR
Undervaluation 80%
Intrinsic Value
Price

See Also

What is Friulchem SpA's Total Current Liabilities?
Total Current Liabilities
17.5m EUR

Based on the financial report for Dec 31, 2023, Friulchem SpA's Total Current Liabilities amounts to 17.5m EUR.

What is Friulchem SpA's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
37%

Over the last year, the Total Current Liabilities growth was -1%. The average annual Total Current Liabilities growth rates for Friulchem SpA have been 46% over the past three years , 37% over the past five years .

Back to Top